RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Checkmate Pharmaceuticals - Stock

Checkmate Pharmaceuticals ROCE 2024

Checkmate Pharmaceuticals ROCE

-0.88

Ticker

CMPI

ISIN

US1628181083

WKN

A2QAMD

In 2024, Checkmate Pharmaceuticals's return on capital employed (ROCE) was -0.88, a 0% increase from the 0 ROCE in the previous year.

Checkmate Pharmaceuticals Aktienanalyse

What does Checkmate Pharmaceuticals do?

Checkmate Pharmaceuticals Inc is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2015 and specializes in the research and development of immuno-oncology therapies. The company has an innovative business model aimed at improving the immune response against cancer. It utilizes the natural ability of the immune system to recognize and eliminate cancer cells. Immuno-oncology is a major trend in cancer therapy today, with the goal of harnessing the body's own immune system to fight cancer cells. Checkmate Pharmaceuticals focuses on the development of unique first-in-class immunotherapeutics. The company collaborates closely with leading academic institutions and international organizations to maximize the potential of its technology and achieve the best results. The business of Checkmate Pharmaceuticals can be divided into three areas, from the Checkmate platform technology, for which multiple patents have been filed, to the two products: CMP-001 (classified as Breakthrough Therapy) and CMP-003. The Checkmate platform technology is based on stimulating immune responses through the ligation of oligonucleotides, which in turn is intended to promote the recognition and elimination of cancer cells. This method aims to safely and effectively harness the benefits of immunotherapy and successfully control the potential hazards of the immune system. CMP-001 is an immunotherapeutic currently in phase 2a clinical development. It is a combination of an adjuvant called STING agonists (also known as Sting-Signalling agonist) and a toll-like receptor-ligand of nucleotide (TLR-9), which help stimulate the body's immune system and trigger an immune response against cancer cells. CMP-001 has been granted 'Breakthrough Therapy' status by the US FDA, meaning that the drug offers a significant advancement in the treatment of patients with serious or life-threatening diseases compared to currently available therapies. CMP-003 is another development by Checkmate Pharmaceuticals, aiming to regulate excessive immune response. Along with STING, antibodies against poxviruses have been shown to activate the immune system and enable effective tumor therapy. One of the main target populations for Checkmate Pharmaceuticals is patients with various types of tumors such as melanoma, small cell lung cancer, and solid tumors that respond to immune system stimulation. Currently, the company is financed by renowned capital investors such as F-Prime Capital, HBM Healthcare Investments, and Sofinnova Investments. The company offers promising perspectives in cancer research and has the potential to deliver further advancements in the field of immuno-oncology with new products. These developments can help make cancer therapy more effective and safer, ultimately moving towards the goal of fighting cancer. Checkmate Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Checkmate Pharmaceuticals's Return on Capital Employed (ROCE)

Checkmate Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Checkmate Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Checkmate Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Checkmate Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Checkmate Pharmaceuticals Stock

What is the ROCE (Return on Capital Employed) of Checkmate Pharmaceuticals this year?

The ROCE of Checkmate Pharmaceuticals is -0.88 undefined this year.

How has the ROCE (Return on Capital Employed) of Checkmate Pharmaceuticals developed compared to the previous year?

The ROCE of Checkmate Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Checkmate Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Checkmate Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Checkmate Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Checkmate Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Checkmate Pharmaceuticals impact the company?

An increase in the ROCE of Checkmate Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Checkmate Pharmaceuticals affect the company?

A decrease in ROCE of Checkmate Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Checkmate Pharmaceuticals?

Some factors that can affect Checkmate Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Checkmate Pharmaceuticals so important for investors?

The ROCE of Checkmate Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Checkmate Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Checkmate Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Checkmate Pharmaceuticals pay?

Over the past 12 months, Checkmate Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Checkmate Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Checkmate Pharmaceuticals?

The current dividend yield of Checkmate Pharmaceuticals is .

When does Checkmate Pharmaceuticals pay dividends?

Checkmate Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Checkmate Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Checkmate Pharmaceuticals located?

Checkmate Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Checkmate Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Checkmate Pharmaceuticals from 7/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/3/2024.

When did Checkmate Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/3/2024.

What was the dividend of Checkmate Pharmaceuticals in the year 2023?

In the year 2023, Checkmate Pharmaceuticals distributed 0 USD as dividends.

In which currency does Checkmate Pharmaceuticals pay out the dividend?

The dividends of Checkmate Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Checkmate Pharmaceuticals

Our stock analysis for Checkmate Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Checkmate Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.